Autopsy report · NCT05144529

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

“Slow enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 6 months before it stopped.
• 19 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Eziafa Oduah, MD, PhD, MPH

Sponsor type

University, hospital or other

Conditions

Lung Cancer Metastatic

Interventions

Nivolumab; Ipilimumab; Evolocumab

Participants

19

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.